Document is current
Any future updates will be listed below
-
Authors
Askan, Gokce
Sahin, Ibrahim Halil.
Chou, Joanne F.
Yavas, Aslihan
Capanu, Marinela
Iacobuzio-Donahue, Christine A.
Basturk, Olca
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008478)
- License Information
-
More Information
Article History
Received: 1 August 2020
Accepted: 29 March 2021
First Online: 9 April 2021
Declarations
:
: Memorial Sloan Kettering IRB & Privacy office reviewed and approved this study and the waiver to allow the use of the data and to permit publication (IRB #17–388). Consent was waived in view of the retrospective nature of the study.
: Not applicable.
: EOR Research Funding to MSK: Genentech/Roche, Celgene/BMS, BioNTech, BioAtla, AstraZeneca, Arcus.EOR Consulting Role: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Sobi, Silenseed, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen (+ spouse), Polaris (+ spouse), Merck (+ spouse), AstraZeneca (+ spouse), Bayer (spouse), Genentech/Roche (spouse), Celgene/BMS (spouse), Eisai (spouse) CID: Research support from BMS.
